all report title image

GASTROENTEROLOGY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Gastroenterology Market, By Drug Type (Biologics/Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents, Others), By Dosage Form (Oral, Parenteral, Others), By Disease Type (Inflammatory Bowel Diseases (IBD), Crohn\'s Disease, Ulcerative Colitis, Irritable Bowel Syndrome (IBS), Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

  • Published In : Sep 2024
  • Code : CMI7416
  • Pages :140
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

Global gastroenterology market growth is driven by rising gastrointestinal disorders such as stomach ulcer, inflammatory bowel disease, irritable bowel syndrome and growing geriatric population that requires effective diagnosis and treatment solutions. Furthermore, technological advancements in gastrointestinal endoscopy devices along with development of novel drugs for gastrointestinal issues can also drive the market growth. Various market players are engaged in new product launches and expansions to cater to increasing needs of healthcare facilities as well as patients. High costs associated with advanced gastroenterology devices and lack of awareness in low-income nations can pose challenges for broader patient access to care.

Market Dynamics:

Global gastroenterology market growth is driven by factors like growing prevalence of gastrointestinal disorders worldwide, increasing geriatric population susceptible to digestive diseases, and advancements in gastrointestinal medical devices. However, high costs associated with gastrointestinal instrumentation and endoscopy devices can hamper the market growth. Emergence of novel oral medicines for gastrointestinal issues and developing healthcare infrastructure in emerging nations can present lucrative opportunities for market expansion. North America dominates the global gasteroenterology market, owing to sizable patient population, fast approval of innovative therapies, and strategic initiatives by market players. However, Asia Pacific is expected to offer high growth prospects due to improving access to specialty care in nations like China and India.

(Key features of the study):

- This report provides in-depth analysis of the global gastroenterology market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global gastroenterology market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Medtronic, Johnson & Johnson, Abbott Laboratories, Hoffmann-La Roche, Bayer AG, GlaxoSmithKline, Sanofi, Pfizer, and Novartis AG

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global gastroenterology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastroenterology market

Detailed Segmentation-

  • By Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Biologics/Biosimilars
    • Antacids
    • Laxatives
    • Antidiarrheal Agents
    • Antiemetics
    • Antiulcer Agents
    • Others
  • By Dosage Form Insights (Revenue, USD Bn, 2019 - 2031)
    • Oral
    • Parenteral
    • Others
  • By Disease Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Inflammatory Bowel Diseases (IBD)
    • Crohn's Disease
    • Ulcerative Colitis
    • Irritable Bowel Syndrome (IBS)
    • Gastroesophageal Reflux Disease (GERD)
    • Liver Diseases
    • Colorectal Cancer
    • Others (Peptic Ulcers, etc.)
  • By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Allied Digestive Health
    • Boston Scientific
    • Capital Digestive Care
    • CRH Medical
    • Iterative Scopes
    • Fujifilm Medical
    • Gastro Health
    • GI Alliance
    • Medtronic
    • Micro-Tech Endoscopy
    • Motus GI
    • Olympus
    • One GI
    • PE GI Solutions
    • Peak Gastroenterology Associates
    • Pentax Medical
    • Pinnacle GI Partners
    • Saneso
    • Surgical Innovations
    • Wision A.I.

Detailed Segmentation-

  • By Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Biologics/Biosimilars
    • Antacids
    • Laxatives
    • Antidiarrheal Agents
    • Antiemetics
    • Antiulcer Agents
    • Others
  • By Dosage Form Insights (Revenue, USD Bn, 2019 - 2031)
    • Oral
    • Parenteral
    • Others
  • By Disease Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Inflammatory Bowel Diseases (IBD)
    • Crohn's Disease
    • Ulcerative Colitis
    • Irritable Bowel Syndrome (IBS)
    • Gastroesophageal Reflux Disease (GERD)
    • Liver Diseases
    • Colorectal Cancer
    • Others (Peptic Ulcers, etc.)
  • By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.